SELLAS Life Sciences (SLS) Cash & Equivalents (2010 - 2026)

SELLAS Life Sciences (SLS) has reported Cash & Equivalents for 17 consecutive years, with $107.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 107000.0% year-over-year to $107.1 million; the TTM figure through Mar 2026 stood at $107.1 million (up 107000.0% YoY), while the FY2025 annual figure was $100000.0, down 99.28% from the prior year.
• Cash & Equivalents grew to $107.1 million in Q1 2026 per SLS's latest filing, from $100000.0 in the prior quarter.
• Across five years, Cash & Equivalents topped out at $107.1 million in Q1 2026 and bottomed at $100000.0 in Q1 2022.
• Historically, Cash & Equivalents has averaged $15.7 million across 5 years, with a median of $4.0 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 99.62% — and 2026, when it soared 107000.0%.
• SELLAS Life Sciences' Cash & Equivalents stood at $17.1 million in 2022, then slumped by 99.42% to $100000.0 in 2023, then surged by 13786.0% to $13.9 million in 2024, then tumbled by 99.28% to $100000.0 in 2025, then jumped by 107000.0% to $107.1 million in 2026.
• Business Quant data shows SLS's Cash & Equivalents at $107.1 million in Q1 2026, $100000.0 in Q4 2025, and $44.3 million in Q3 2025.